CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines (Business Wire)

CONMED Corporation announced plans to exit its gastroenterology product lines, accelerating a strategic shift toward its core markets in minimally invasive, robotic, laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair. The move will end its distribution of the Gore® VIABIL® biliary stent by January 2026 and is expected to generate near-term EPS dilution, while improving the company’s long-term margin profile and capital allocation flexibility.